- Home
- ACN vs SNY Comparison
ACN vs SNY Comparison
Compare ACN & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACN | SNY |
|---|---|---|
| Founded | 1989 | 1994 |
| Country | Ireland | France |
| Employees | N/A | 74846 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.2B | 110.4B |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACN | SNY |
|---|---|---|
| Price | $177.47 | $43.87 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 5 |
| Target Price | ★ $270.81 | $58.00 |
| AVG Volume (30 Days) | ★ 4.6M | 2.6M |
| Earning Date | 03-19-2026 | 04-23-2026 |
| Dividend Yield | ★ 3.62% | 3.47% |
| EPS Growth | ★ 6.21 | N/A |
| EPS | ★ 6.47 | N/A |
| Revenue | ★ $69,672,977,000.00 | N/A |
| Revenue This Year | $7.44 | $3.49 |
| Revenue Next Year | $5.26 | $6.10 |
| P/E Ratio | $27.54 | ★ $6.14 |
| Revenue Growth | ★ 7.36 | N/A |
| 52 Week Low | $173.56 | $43.10 |
| 52 Week High | $322.86 | $53.36 |
Technical Indicators
Market Signals| Indicator | ACN | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 35.60 | 35.07 |
| Support Level | N/A | $43.32 |
| Resistance Level | $200.91 | $48.76 |
| Average True Range (ATR) | 5.62 | 0.71 |
| MACD | -0.07 | -0.44 |
| Stochastic Oscillator | 12.40 | 14.71 |
Price Performance
Historical ComparisonAbout ACN Accenture plc (Ireland)
Accenture is a leading IT services firm that provides consulting, system integration, and business process outsourcing to enterprises around the world. Customers of Accenture come from a variety of sectors, including communications, media and technology, financial services, health and public services, consumer products, and resources. Accenture is the world's largest professional services company by headcount with around 800,000 employees in over 120 countries.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.